Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market BioSpaceRegeneron's Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen's Sohonos.Rare DiseaseRead full story pharminent August 20, 2026 (Last updated: August 23, 2026) BioSpace Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. Rare Disease Read full story Post navigation Previous: Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureNext: Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026